A Fresh Look at Artivion (AORT) Valuation After Strong Q3 Results and Raised 2025 Guidance

Simply Wall St.11-07

Artivion (AORT) grabbed investor attention after announcing a strong third quarter, with revenue and profit jumping compared to last year. Alongside these results, management raised full-year guidance...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581988364?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2025-11-07 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581988364","market":"nz","top_or_hot":-1,"title":"A Fresh Look at Artivion (AORT) Valuation After Strong Q3 Results and Raised 2025 Guidance","media":"Simply Wall St.","content":"<div>\n<p>Artivion (AORT) grabbed investor attention after announcing a strong third quarter, with revenue and profit jumping compared to last year. Alongside these results, management raised full-year guidance...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/a-fresh-look-at-artivion-aort-valuation-after-strong-q3-resu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Fresh Look at Artivion (AORT) Valuation After Strong Q3 Results and Raised 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Fresh Look at Artivion (AORT) Valuation After Strong Q3 Results and Raised 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-07 20:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/a-fresh-look-at-artivion-aort-valuation-after-strong-q3-resu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Artivion (AORT) grabbed investor attention after announcing a strong third quarter, with revenue and profit jumping compared to last year. Alongside these results, management raised full-year guidance...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/a-fresh-look-at-artivion-aort-valuation-after-strong-q3-resu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B7SZL793.SGD","symbol_name":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/a-fresh-look-at-artivion-aort-valuation-after-strong-q3-resu","article_id":"2581988364","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/a-fresh-look-at-artivion-aort-valuation-after-strong-q3-resu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2581988364","pubTimestamp":1762519096,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Artivion (AORT) grabbed investor attention after announcing a strong third quarter, with revenue and profit jumping compared to last year. Alongside these results, management raised full-year guidance for 2025, citing sustained business momentum.\nSee our latest analysis for Artivion.\nStrong execution and a string of positive updates have fueled Artivion’s momentum, with the stock up over 69% so far this year and a total shareholder return of nearly 64% over the past twelve months. The market...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","BK4082":"医疗保健设备","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","AORT":"Artivion","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC"},"translate_title":"第三季度业绩强劲并上调2025年指引后，重新审视Artivion(AORT)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AORT":1.5},"content_text":"Artivion (AORT) grabbed investor attention after announcing a strong third quarter, with revenue and profit jumping compared to last year. Alongside these results, management raised full-year guidance for 2025, citing sustained business momentum. See our latest analysis for Artivion. Strong execution and a string of positive updates have fueled Artivion’s momentum, with the stock up over 69% so far this year and a total shareholder return of nearly 64% over the past twelve months. The market response suggests investors are optimistic about growth prospects, especially as major trials and new guidance contribute to the story. If you’re curious what other healthcare innovators are capturing attention right now, it’s a great time to explore the sector. See the full list for free with our See the full list for free.. With shares already surging nearly 70 percent this year, the key question is whether Artivion remains undervalued after its run, or if the market is simply reflecting expectations for continued strong growth. Investors may wonder if there is still a buying opportunity, or if future upside has already been priced in. AdvertisementMost Popular Narrative: 5% Overvalued With Artivion's fair value in the most popular narrative coming in slightly below the last close, market enthusiasm is running above the analysts' consensus. This gap hints at high expectations being priced in.  Continued progress in obtaining regulatory approvals and launching products (e.g., BioGlue in China, Arcevo LSA pivotal trial in the U.S., and potential NEXUS approval via Endospan acquisition) is extending Artivion's geographic reach and product offerings. This is unlocking new growth regions and revenue streams while further diversifying earnings.  Read the complete narrative. What are the bold growth projections hidden inside this fair value? The narrative relies on ambitious profit leaps, margin boosts, and a future multiple more typical of high-growth disruptors. Want to know what assumptions are generating this premium? You’ll want to dig into the full story behind these numbers. Result: Fair Value of $45.26 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the narrative could shift if Artivion’s clinical pipeline faces regulatory setbacks, or if persistent supply disruptions impact revenue consistency. Find out about the key risks to this Artivion narrative.  Build Your Own Artivion Narrative Curious to see if your perspective matches up, or ready to put your own analysis to the test? It's quick and easy to craft your own take on Artivion's outlook in just a few minutes, so why not Do it your way A great starting point for your Artivion research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision. Looking for More Investment Ideas? Don't let other high-potential opportunities pass you by. Take charge and broaden your investment research by tapping into these hand-picked stock lists designed for serious investors.  Boost your portfolio's passive income with a selection of companies offering yields over 3 percent when you tap into these 17 dividend stocks with yields > 3%. Uncover digital innovation at its source and gain exposure to the hottest blockchain and crypto trends with these 82 cryptocurrency and blockchain stocks. Seize the chance to find tomorrow's most promising undervalued stocks grounded in strong cash flows via these 861 undervalued stocks based on cash flows.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581988364","isCrawlerRequest":true}